Hillary Lum
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Advance Care Planning | 45 | 2024 | 222 | 15.520 |
Why?
| | Palliative Care | 19 | 2025 | 817 | 3.610 |
Why?
| | Dementia | 8 | 2025 | 263 | 3.210 |
Why?
| | Patient Portals | 7 | 2024 | 45 | 3.100 |
Why?
| | Caregivers | 14 | 2025 | 932 | 2.400 |
Why?
| | Primary Health Care | 15 | 2024 | 1799 | 2.030 |
Why?
| | Patient Participation | 6 | 2024 | 432 | 2.030 |
Why?
| | Hospice Care | 5 | 2023 | 201 | 1.800 |
Why?
| | Aged | 65 | 2025 | 24574 | 1.790 |
Why?
| | Physicians | 9 | 2024 | 934 | 1.720 |
Why?
| | Suicide, Assisted | 6 | 2024 | 26 | 1.720 |
Why?
| | Terminal Care | 6 | 2023 | 251 | 1.720 |
Why?
| | Advance Directives | 9 | 2024 | 81 | 1.590 |
Why?
| | Communication | 15 | 2024 | 945 | 1.580 |
Why?
| | Skilled Nursing Facilities | 7 | 2024 | 140 | 1.580 |
Why?
| | Physician-Patient Relations | 9 | 2024 | 583 | 1.540 |
Why?
| | Huntington Disease | 2 | 2024 | 64 | 1.510 |
Why?
| | Electronic Health Records | 7 | 2024 | 1122 | 1.360 |
Why?
| | Aged, 80 and over | 27 | 2025 | 7856 | 1.310 |
Why?
| | Documentation | 5 | 2024 | 199 | 1.280 |
Why?
| | Humans | 125 | 2025 | 141187 | 1.250 |
Why?
| | Parkinson Disease | 3 | 2020 | 569 | 1.190 |
Why?
| | Pandemics | 7 | 2022 | 1653 | 1.180 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 403 | 1.170 |
Why?
| | Subacute Care | 5 | 2024 | 79 | 1.160 |
Why?
| | Volunteers | 2 | 2019 | 40 | 1.160 |
Why?
| | Surveys and Questionnaires | 21 | 2024 | 5929 | 1.160 |
Why?
| | Hospices | 2 | 2022 | 88 | 1.120 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1448 | 1.100 |
Why?
| | Heart Failure | 7 | 2023 | 2088 | 1.090 |
Why?
| | Social Isolation | 2 | 2025 | 66 | 1.090 |
Why?
| | Qualitative Research | 16 | 2025 | 1516 | 1.090 |
Why?
| | Loneliness | 2 | 2025 | 50 | 1.080 |
Why?
| | Quality Improvement | 6 | 2023 | 1244 | 1.030 |
Why?
| | Home Care Services | 5 | 2023 | 259 | 0.940 |
Why?
| | Adult Children | 1 | 2025 | 26 | 0.920 |
Why?
| | Male | 58 | 2025 | 69783 | 0.910 |
Why?
| | Object Attachment | 1 | 2025 | 48 | 0.890 |
Why?
| | Female | 63 | 2025 | 75515 | 0.880 |
Why?
| | Authorship | 1 | 2024 | 54 | 0.840 |
Why?
| | Home Health Aides | 1 | 2023 | 6 | 0.840 |
Why?
| | Patient Care Team | 4 | 2025 | 664 | 0.840 |
Why?
| | Medical Marijuana | 3 | 2020 | 125 | 0.810 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 88 | 0.780 |
Why?
| | Life Support Care | 2 | 2020 | 39 | 0.780 |
Why?
| | Medicare | 5 | 2024 | 799 | 0.770 |
Why?
| | Group Processes | 2 | 2020 | 65 | 0.760 |
Why?
| | Middle Aged | 29 | 2025 | 34434 | 0.760 |
Why?
| | Health Services for the Aged | 2 | 2020 | 73 | 0.760 |
Why?
| | Parent-Child Relations | 1 | 2025 | 285 | 0.740 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2020 | 1396 | 0.740 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 305 | 0.740 |
Why?
| | Feasibility Studies | 3 | 2024 | 1018 | 0.700 |
Why?
| | Living Wills | 1 | 2020 | 8 | 0.680 |
Why?
| | Housing | 1 | 2022 | 145 | 0.680 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1336 | 0.670 |
Why?
| | Outpatients | 2 | 2024 | 420 | 0.670 |
Why?
| | Music Therapy | 1 | 2020 | 25 | 0.670 |
Why?
| | Alzheimer Disease | 2 | 2025 | 583 | 0.650 |
Why?
| | Patient-Centered Care | 3 | 2021 | 550 | 0.650 |
Why?
| | Mass Screening | 2 | 2025 | 1310 | 0.650 |
Why?
| | Music | 1 | 2020 | 44 | 0.650 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 677 | 0.630 |
Why?
| | Inservice Training | 2 | 2017 | 122 | 0.620 |
Why?
| | Virtual Reality | 1 | 2020 | 71 | 0.610 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 140 | 0.610 |
Why?
| | Ambulatory Care Facilities | 2 | 2019 | 248 | 0.590 |
Why?
| | Sports | 1 | 2021 | 219 | 0.590 |
Why?
| | Pharmacists | 1 | 2021 | 263 | 0.590 |
Why?
| | CD40 Antigens | 4 | 2006 | 89 | 0.580 |
Why?
| | Internship and Residency | 2 | 2021 | 1235 | 0.580 |
Why?
| | Resuscitation Orders | 4 | 2024 | 46 | 0.580 |
Why?
| | Stakeholder Participation | 1 | 2019 | 81 | 0.570 |
Why?
| | Attitude of Health Personnel | 7 | 2024 | 1171 | 0.570 |
Why?
| | Activities of Daily Living | 1 | 2022 | 424 | 0.570 |
Why?
| | Independent Living | 2 | 2018 | 107 | 0.560 |
Why?
| | Hospitalization | 5 | 2023 | 2255 | 0.550 |
Why?
| | Long-Term Care | 3 | 2024 | 110 | 0.540 |
Why?
| | Geriatric Assessment | 2 | 2024 | 221 | 0.540 |
Why?
| | Betacoronavirus | 1 | 2020 | 276 | 0.530 |
Why?
| | Patient Discharge | 5 | 2024 | 932 | 0.520 |
Why?
| | Nursing Homes | 4 | 2024 | 171 | 0.520 |
Why?
| | Geriatrics | 3 | 2024 | 93 | 0.510 |
Why?
| | Physicians, Primary Care | 1 | 2019 | 226 | 0.510 |
Why?
| | Clinical Protocols | 1 | 2018 | 273 | 0.500 |
Why?
| | Perception | 2 | 2020 | 376 | 0.500 |
Why?
| | Social Media | 1 | 2019 | 161 | 0.490 |
Why?
| | Parents | 1 | 2025 | 1434 | 0.490 |
Why?
| | Interviews as Topic | 5 | 2024 | 844 | 0.480 |
Why?
| | Nurse Practitioners | 1 | 2018 | 141 | 0.480 |
Why?
| | Patient Education as Topic | 5 | 2019 | 778 | 0.470 |
Why?
| | Marijuana Use | 4 | 2020 | 221 | 0.470 |
Why?
| | Policy | 1 | 2016 | 149 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.460 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.460 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.450 |
Why?
| | Drug Utilization | 1 | 2015 | 169 | 0.440 |
Why?
| | Life Change Events | 1 | 2015 | 153 | 0.430 |
Why?
| | United States | 15 | 2025 | 15220 | 0.420 |
Why?
| | Health Services Accessibility | 2 | 2021 | 1016 | 0.420 |
Why?
| | Patient Readmission | 4 | 2021 | 706 | 0.410 |
Why?
| | Education, Medical | 1 | 2017 | 270 | 0.410 |
Why?
| | Patient Care Planning | 3 | 2020 | 155 | 0.410 |
Why?
| | Physician's Role | 1 | 2015 | 219 | 0.410 |
Why?
| | Pilot Projects | 7 | 2025 | 1820 | 0.410 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 331 | 0.400 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5636 | 0.390 |
Why?
| | Decision Making | 4 | 2017 | 961 | 0.390 |
Why?
| | Nurses | 1 | 2015 | 184 | 0.380 |
Why?
| | Culture | 1 | 2012 | 130 | 0.350 |
Why?
| | Patient Navigation | 2 | 2025 | 98 | 0.350 |
Why?
| | Canada | 5 | 2023 | 428 | 0.350 |
Why?
| | Adult | 14 | 2025 | 39177 | 0.350 |
Why?
| | Melanoma, Experimental | 3 | 2006 | 111 | 0.350 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2172 | 0.350 |
Why?
| | Emergency Medical Services | 1 | 2018 | 647 | 0.350 |
Why?
| | Interpersonal Relations | 1 | 2014 | 411 | 0.340 |
Why?
| | Quality of Life | 3 | 2023 | 2999 | 0.330 |
Why?
| | Patients | 1 | 2012 | 180 | 0.330 |
Why?
| | Health Status | 1 | 2016 | 823 | 0.330 |
Why?
| | Health Information Exchange | 2 | 2021 | 24 | 0.330 |
Why?
| | Telemedicine | 4 | 2025 | 891 | 0.320 |
Why?
| | Depression | 3 | 2018 | 1483 | 0.320 |
Why?
| | Retrospective Studies | 7 | 2024 | 16273 | 0.310 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1304 | 0.310 |
Why?
| | Cardiac Surgical Procedures | 2 | 2025 | 585 | 0.310 |
Why?
| | Electronic Mail | 2 | 2019 | 62 | 0.300 |
Why?
| | Health Communication | 2 | 2019 | 48 | 0.280 |
Why?
| | Influenza, Human | 1 | 2014 | 626 | 0.270 |
Why?
| | Peer Group | 2 | 2020 | 247 | 0.270 |
Why?
| | Neuroblastoma | 2 | 2006 | 163 | 0.270 |
Why?
| | Hospital Mortality | 1 | 2012 | 924 | 0.270 |
Why?
| | Organizations, Nonprofit | 1 | 2007 | 18 | 0.270 |
Why?
| | Colorado | 9 | 2024 | 4610 | 0.260 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 339 | 0.260 |
Why?
| | Social Work | 3 | 2024 | 85 | 0.250 |
Why?
| | Referral and Consultation | 4 | 2024 | 798 | 0.250 |
Why?
| | Emergence Delirium | 1 | 2025 | 7 | 0.240 |
Why?
| | Health Resources | 1 | 2007 | 129 | 0.240 |
Why?
| | Automobile Driving | 2 | 2019 | 151 | 0.230 |
Why?
| | Grounded Theory | 1 | 2025 | 36 | 0.230 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 245 | 0.230 |
Why?
| | Immunotherapy | 2 | 2008 | 640 | 0.220 |
Why?
| | Immunization, Passive | 1 | 2005 | 90 | 0.220 |
Why?
| | Empathy | 2 | 2025 | 174 | 0.220 |
Why?
| | Telerehabilitation | 1 | 2025 | 38 | 0.220 |
Why?
| | Multimorbidity | 1 | 2025 | 53 | 0.220 |
Why?
| | Delirium | 1 | 2025 | 105 | 0.210 |
Why?
| | Antibodies, Bispecific | 1 | 2005 | 60 | 0.210 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2087 | 0.210 |
Why?
| | Oncologists | 1 | 2024 | 44 | 0.210 |
Why?
| | Neurology | 1 | 2025 | 111 | 0.210 |
Why?
| | Internet | 2 | 2018 | 690 | 0.200 |
Why?
| | Elder Abuse | 1 | 2024 | 51 | 0.200 |
Why?
| | Neoplasms | 3 | 2024 | 2741 | 0.200 |
Why?
| | Self Concept | 1 | 2025 | 262 | 0.200 |
Why?
| | T-Lymphocytes | 4 | 2006 | 2002 | 0.200 |
Why?
| | Sleep Aids, Pharmaceutical | 1 | 2022 | 4 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2021 | 666 | 0.190 |
Why?
| | Information Dissemination | 1 | 2024 | 224 | 0.190 |
Why?
| | Video Recording | 2 | 2025 | 190 | 0.180 |
Why?
| | Interleukin-2 | 3 | 2009 | 453 | 0.180 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 16 | 0.180 |
Why?
| | Death | 1 | 2022 | 125 | 0.180 |
Why?
| | Macrophages, Peritoneal | 3 | 2006 | 97 | 0.180 |
Why?
| | Digital Divide | 1 | 2021 | 3 | 0.180 |
Why?
| | Endothelium, Vascular | 3 | 2011 | 951 | 0.170 |
Why?
| | Macrophages | 2 | 2006 | 1561 | 0.170 |
Why?
| | Recovery of Function | 1 | 2025 | 678 | 0.170 |
Why?
| | Nitric Oxide | 1 | 2006 | 900 | 0.170 |
Why?
| | HIV-1 | 1 | 2007 | 895 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1250 | 0.170 |
Why?
| | Hearing Loss | 1 | 2024 | 222 | 0.170 |
Why?
| | Patient Selection | 1 | 2025 | 688 | 0.170 |
Why?
| | Comorbidity | 2 | 2016 | 1662 | 0.170 |
Why?
| | Deprescriptions | 1 | 2021 | 37 | 0.170 |
Why?
| | Personhood | 1 | 2020 | 5 | 0.170 |
Why?
| | Geriatric Psychiatry | 1 | 2020 | 12 | 0.170 |
Why?
| | Program Evaluation | 1 | 2025 | 928 | 0.160 |
Why?
| | Macrophage Activation | 3 | 2006 | 200 | 0.160 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1085 | 0.160 |
Why?
| | Multiple Chronic Conditions | 1 | 2020 | 31 | 0.160 |
Why?
| | Receptors, GABA-A | 1 | 2021 | 141 | 0.160 |
Why?
| | Perioperative Care | 1 | 2022 | 227 | 0.160 |
Why?
| | Organization and Administration | 1 | 2019 | 14 | 0.160 |
Why?
| | Health Expenditures | 1 | 2021 | 193 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 192 | 0.160 |
Why?
| | Europe | 1 | 2020 | 410 | 0.150 |
Why?
| | Patient Preference | 2 | 2022 | 205 | 0.150 |
Why?
| | Health Plan Implementation | 1 | 2020 | 145 | 0.150 |
Why?
| | Veterans | 2 | 2025 | 1514 | 0.150 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 83 | 0.150 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.150 |
Why?
| | Medical Futility | 1 | 2018 | 28 | 0.150 |
Why?
| | Inpatients | 1 | 2023 | 507 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 26 | 0.140 |
Why?
| | Community-Institutional Relations | 1 | 2019 | 101 | 0.140 |
Why?
| | Delphi Technique | 2 | 2017 | 308 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4073 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2001 | 244 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.140 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 19 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1597 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2006 | 226 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 382 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 289 | 0.140 |
Why?
| | Mentoring | 1 | 2020 | 151 | 0.130 |
Why?
| | Research Personnel | 1 | 2019 | 183 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 1048 | 0.130 |
Why?
| | Ecosystem | 1 | 2022 | 583 | 0.130 |
Why?
| | Reading | 1 | 2018 | 136 | 0.130 |
Why?
| | Rural Population | 1 | 2022 | 604 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 368 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2022 | 658 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2902 | 0.130 |
Why?
| | Health Services Research | 1 | 2019 | 406 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2025 | 2797 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 528 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2020 | 349 | 0.120 |
Why?
| | Universities | 1 | 2019 | 452 | 0.120 |
Why?
| | Community Health Services | 1 | 2018 | 233 | 0.120 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 174 | 0.120 |
Why?
| | Hypesthesia | 1 | 2016 | 19 | 0.120 |
Why?
| | Cannabis | 2 | 2020 | 512 | 0.120 |
Why?
| | Housing for the Elderly | 1 | 2015 | 7 | 0.120 |
Why?
| | Disease Management | 2 | 2019 | 633 | 0.120 |
Why?
| | Financing, Personal | 1 | 2015 | 28 | 0.120 |
Why?
| | Pain Management | 1 | 2019 | 396 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 96 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 750 | 0.110 |
Why?
| | Workflow | 1 | 2016 | 171 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 7739 | 0.110 |
Why?
| | Professional Role | 1 | 2016 | 168 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2017 | 244 | 0.110 |
Why?
| | Young Adult | 3 | 2021 | 13673 | 0.110 |
Why?
| | Environment | 1 | 2016 | 341 | 0.110 |
Why?
| | Firearms | 1 | 2020 | 390 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2001 | 1330 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 1033 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 464 | 0.100 |
Why?
| | Cell Line, Tumor | 6 | 2009 | 3469 | 0.100 |
Why?
| | Cytokines | 4 | 2006 | 2098 | 0.100 |
Why?
| | Communication Barriers | 1 | 2014 | 116 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2016 | 368 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2015 | 118 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1049 | 0.100 |
Why?
| | State Medicine | 1 | 2012 | 25 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1490 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3017 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 433 | 0.090 |
Why?
| | Risk Factors | 4 | 2025 | 10438 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 878 | 0.090 |
Why?
| | Stroke | 1 | 2020 | 1154 | 0.090 |
Why?
| | Glucuronidase | 1 | 2011 | 44 | 0.090 |
Why?
| | Attitude to Health | 1 | 2015 | 458 | 0.090 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2011 | 25 | 0.090 |
Why?
| | Benzodiazepines | 2 | 2022 | 156 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1816 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2892 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 1990 | 72 | 0.080 |
Why?
| | Goals | 2 | 2022 | 179 | 0.080 |
Why?
| | Prevalence | 1 | 2016 | 2772 | 0.070 |
Why?
| | Mice, SCID | 2 | 2006 | 367 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 630 | 0.070 |
Why?
| | Killer Cells, Natural | 3 | 2006 | 469 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 672 | 0.070 |
Why?
| | Nigeria | 1 | 2007 | 23 | 0.070 |
Why?
| | Signal Transduction | 1 | 2001 | 5144 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 1990 | 410 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2011 | 361 | 0.070 |
Why?
| | Adolescent | 3 | 2021 | 22007 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 246 | 0.070 |
Why?
| | Immunologic Memory | 1 | 2009 | 360 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2020 | 11120 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2011 | 404 | 0.060 |
Why?
| | Hospitals | 2 | 2022 | 696 | 0.060 |
Why?
| | Religion | 1 | 2007 | 68 | 0.060 |
Why?
| | Mice | 8 | 2009 | 18048 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2006 | 5887 | 0.060 |
Why?
| | Animals | 12 | 2011 | 37657 | 0.060 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2006 | 49 | 0.060 |
Why?
| | Mice, Inbred A | 1 | 2006 | 51 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 25 | 0.060 |
Why?
| | Toll-Like Receptor 9 | 1 | 2006 | 33 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1128 | 0.060 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 250 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 309 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 242 | 0.060 |
Why?
| | Mental Status and Dementia Tests | 1 | 2025 | 27 | 0.060 |
Why?
| | Vaccination | 1 | 2014 | 1467 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 142 | 0.060 |
Why?
| | Self Report | 2 | 2019 | 856 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2006 | 220 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3348 | 0.060 |
Why?
| | CD3 Complex | 1 | 2005 | 106 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 7 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 959 | 0.050 |
Why?
| | Postoperative Period | 1 | 2025 | 355 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 1150 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2005 | 125 | 0.050 |
Why?
| | Specialization | 1 | 2024 | 130 | 0.050 |
Why?
| | Terminally Ill | 1 | 2023 | 37 | 0.050 |
Why?
| | Epidemics | 1 | 2024 | 92 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 112 | 0.050 |
Why?
| | Morals | 1 | 2023 | 75 | 0.050 |
Why?
| | Preoperative Care | 1 | 2025 | 371 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 578 | 0.050 |
Why?
| | Pregnancy Proteins | 1 | 2002 | 35 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 889 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 854 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3292 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2005 | 346 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 892 | 0.050 |
Why?
| | Patient Care | 1 | 2023 | 120 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2005 | 792 | 0.040 |
Why?
| | Cohort Studies | 1 | 2012 | 5799 | 0.040 |
Why?
| | Rats | 2 | 2011 | 5629 | 0.040 |
Why?
| | Asia | 1 | 2021 | 70 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 178 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1282 | 0.040 |
Why?
| | Senior Centers | 1 | 2019 | 1 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 75 | 0.040 |
Why?
| | Ownership | 1 | 2020 | 100 | 0.040 |
Why?
| | Leukocytes | 1 | 2001 | 309 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 296 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 358 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2794 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 73 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 292 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2020 | 169 | 0.040 |
Why?
| | Safety | 1 | 2020 | 356 | 0.040 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 150 | 0.040 |
Why?
| | Minority Health | 1 | 2018 | 18 | 0.040 |
Why?
| | Social Values | 1 | 2018 | 40 | 0.030 |
Why?
| | Informed Consent | 1 | 2019 | 189 | 0.030 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 26 | 0.030 |
Why?
| | California | 1 | 2018 | 462 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 158 | 0.030 |
Why?
| | Students | 1 | 2021 | 645 | 0.030 |
Why?
| | Racism | 1 | 2018 | 139 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1306 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 335 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3490 | 0.030 |
Why?
| | Time Factors | 3 | 2020 | 6956 | 0.030 |
Why?
| | Personal Autonomy | 1 | 2015 | 49 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 961 | 0.020 |
Why?
| | Pain | 1 | 2018 | 781 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2008 | 1197 | 0.020 |
Why?
| | Spleen | 2 | 2004 | 525 | 0.020 |
Why?
| | Streptozocin | 1 | 2011 | 23 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1082 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 1990 | 47 | 0.020 |
Why?
| | Gerbillinae | 1 | 1990 | 71 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 199 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 1989 | 82 | 0.020 |
Why?
| | Pressure | 1 | 1990 | 229 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 339 | 0.020 |
Why?
| | Albumins | 1 | 1989 | 115 | 0.020 |
Why?
| | Thrombin | 1 | 1989 | 170 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1989 | 266 | 0.020 |
Why?
| | Child | 1 | 2007 | 22308 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2064 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1274 | 0.020 |
Why?
| | Apoptosis | 2 | 2006 | 2574 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1243 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2009 | 313 | 0.010 |
Why?
| | Cell Division | 2 | 2002 | 798 | 0.010 |
Why?
| | Glucose | 1 | 2011 | 1041 | 0.010 |
Why?
| | Leukemia L5178 | 1 | 2005 | 1 | 0.010 |
Why?
| | CpG Islands | 1 | 2006 | 163 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2520 | 0.010 |
Why?
| | Cell Line | 1 | 2011 | 2885 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 138 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 898 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 270 | 0.010 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2004 | 26 | 0.010 |
Why?
| | Gangliosides | 1 | 2004 | 22 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2005 | 245 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2006 | 329 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 273 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 412 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 667 | 0.010 |
Why?
| | Megakaryocytes | 1 | 2002 | 36 | 0.010 |
Why?
| | CHO Cells | 1 | 2002 | 168 | 0.010 |
Why?
| | Cricetinae | 1 | 2002 | 301 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1074 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 674 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 325 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4404 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1357 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2002 | 411 | 0.010 |
Why?
| | Gestational Age | 1 | 2002 | 957 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2005 | 3068 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 802 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 2003 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4208 | 0.010 |
Why?
| | Pregnancy | 1 | 2002 | 7070 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1989 | 417 | 0.000 |
Why?
| | Actins | 1 | 1989 | 423 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 998 | 0.000 |
Why?
| | Cell Survival | 1 | 1989 | 1129 | 0.000 |
Why?
| | Cell Membrane | 1 | 1989 | 724 | 0.000 |
Why?
|
|
Lum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|